What is Veracyte, Inc. (VCYT)?

Veracyte, Inc. (VCYT) is a stock in the Healthcare sector, Medical - Diagnostics & Research industry. View full analysis on Stocks360.

What is the current price of VCYT?

The current price of VCYT is $52.17. Prices are updated in real time on Stocks360.

What is VCYT's price-to-earnings (PE) ratio?

VCYT's trailing twelve-month PE ratio is 36.23, based on current price and earnings per share data available on Stocks360.

What is VCYT's market capitalization?

VCYT's market capitalization is $4,193,982,819.00, placing it in the mid-cap tier.

Veracyte, Inc. (VCYT)

Stock analysis · NASDAQ · Healthcare · Medical - Diagnostics & Research

$52.17

Market Cap

$4.19B

PE (TTM)

36.23

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.95

Day Range

$49.63 – $52.39

52-wk Range

$29.46 – $60.91

Avg Volume

N/A

Volume

1.23M

Veracyte, Inc. (VCYT) is a publicly traded company in the Healthcare sector. Latest price: $52.17. Market cap $4.19B. Trailing PE 36.23. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 5 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-30 · $35.33 2026-10-29 · $52.17 (+47.66%)

Earnings

Most Recent

Jul 30, 2026

EPS $0.54 vs est. $0.41

Beat by $0.13

Next Earnings

Nov 4, 2026

EPS estimate $0.41

Proprietary Signals

Signal snapshot temporarily unavailable.

About Veracyte, Inc.

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	36.23×
P/S (TTM)	7.46×
P/B	2.99×
PEG	0.12×
P/FCF (TTM)	25.35×
EV / EBITDA	30.32×
EV / Sales	7.00×
Earnings Yield	2.75%
Free Cash Flow Yield	3.95%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$3.93B
Revenue (TTM)	$561.90M
Net Income (TTM)	$115.54M
Free Cash Flow (TTM)	$165.99M
Net Debt	-$259.41M
Working Capital	$512.04M
Gross Margin	72.09%
Operating Margin	17.03%
Net Margin	20.37%
Return on Equity	8.64%
Return on Invested Capital	6.70%